BioCentury | Mar 25, 2019
Emerging Company Profile

China Oncology Focus: funding combinations

...COF also plans to submit ANDAs in China this year for generic versions of Inlyta, Evomela...
...1 ligand 1 TOP1 - Topoisomerase I Hongjiang Li, Staff Writer Evomela (Brand), melphalan (Generic), IV Captisol-enabled Melphalan (Informal), Evomela...
BioCentury | Jan 18, 2019
Company News

Spectrum divesting marketed products to focus on late-stage programs

...lymphoma drug Zevalin ibritumomab tiuxetan, acute lymphoblastic leukemia drug Marqibo vincristine and multiple myeloma drug Evomela...
...BSE:524804), Hyderabad, India Business: Cancer Chris Lieu Beleodaq, belinostat (IV PXD101, PXD101) Evomela (Brand), melphalan (Generic), IV Captisol-enabled Melphalan (Informal), Evomela...
BioCentury | Jan 17, 2019
Company News

Spectrum divesting marketed products to focus on late-stage programs

...lymphoma drug Zevalin ibritumomab tiuxetan, acute lymphoblastic leukemia drug Marqibo vincristine and multiple myeloma drug Evomela...
...Epidermal growth factor receptor 2 Chris Lieu Beleodaq, belinostat (IV PXD101, PXD101) Evomela (Brand), melphalan (Generic), IV Captisol-enabled Melphalan (Informal), Evomela...
BioCentury | Apr 13, 2018
Clinical News

China advisory committee to review CASI's multiple myeloma therapy

...China's Expert Advisory Anti-Tumor (Oncology) Drugs Committee will meet to review an application for CASI's Evomela...
...China FDA's Center for Drug Evaluation told CASI the review is scheduled for April 25-26. Evomela...
...on April 6. CASI Pharmaceuticals Inc. (NASDAQ:CASI), Rockville, Md. Product: Evomela melphalan (IV Captisol-enabled Melphalan) Business: Transplant Sandi Wong Evomela CASI...
BioCentury | Oct 27, 2017
Financial News

CASI raises $23.9M in registered direct offering

...to purchase 0.2 shares, with each whole warrant exercisable at $3.75. The company said its Evomela...
BioCentury | Dec 12, 2016
Clinical News

Evomela regulatory update

...and Drug Administration (CFDA) accepted for review an import drug registration application from CASI for Evomela...
...deal (see BioCentury, March 18, 2013 ). In 2014, Spectrum granted CASI exclusive rights to Evomela...
...La Jolla, Calif. Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI), Henderson, Nev. Product: Evomela melphalan (IV Captisol-enabled Melphalan) Business: Transplant Alex Himes Evomela IV Captisol-enabled Melphalan CASI...
BioCentury | Mar 28, 2016
Clinical News

Evomela melphalan regulatory update

...FDA approved an NDA from Spectrum for Evomela melphalan as a high-dose conditioning treatment in patients...
...Inc. (NASDAQ:LGND), La Jolla, Calif. Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI), Henderson, Nev. Product: Evomela melphalan ( IV Captisol-enabled Melphalan...
BioCentury | Nov 9, 2015
Clinical News

Melphalan regulatory update

...FDA issued a complete response letter to Spectrum for an NDA for Evomela melphalan as a...
...NASDAQ:LGND), La Jolla, Calif. Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI), Henderson, Nev. Product: Melphalan ( IV Captisol-enabled Melphalan , Evomela...
BioCentury | Oct 5, 2015
Finance

Event planner

...moderately severe pain Submit NDA 4Q15 Ligand Pharmaceuticals Inc. (NASDAQ:LGND) / Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) Evomela...
BioCentury | Jul 13, 2015
Finance

Big news

...Carcinoid syndrome Ph III data 3Q15 Ligand Pharmaceuticals Inc. (NASDAQ:LGND) / Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) Evomela...
Items per page:
1 - 10 of 19